Loading...
Back
NFLR
FRX
INFLARX NV
(IFRX)
2025 6-K
Follow
Summary
Share
Summary
Share Offering Update
7 May '26
Izicopan Development Update
6 May '26
Financial Report
6 May '26
Izicopan Developments
4 May '26
Compliance Regained
28 Apr '26
Annual Meeting Results
23 Apr '26
Research Findings
9 Apr '26
Annual Meeting Notice
2 Apr '26
Annual Results Report
19 Mar '26
Nasdaq Compliance Notice
13 Mar '26
Company Restructuring
8 Jan '26
Phase 3 Analysis Update
30 Dec '25
Positive Trial Results
10 Nov '25
Financial Report
10 Nov '25
NASDAQ Compliance Regained
12 Sep '25
Filing Report Summary
7 Aug '25
Nasdaq Compliance Notice
14 Jul '25
Accounting Change
27 Jun '25
Trial Stopped
28 May '25
Financial Update
7 May '25
Annual Meeting Results
24 Apr '25
Annual Meeting Notice
3 Apr '25
Annual Results Report
20 Mar '25
Share Offering Details
18 Feb '25
EU Approval Granted
15 Jan '25
Patient Study Dosage
20 Dec '24
Positive CHMP Opinion
15 Nov '24
Financial Report
8 Nov '24
Financial Report Update
8 Aug '24
Sales Agreement
28 Jun '24
Clinical Trial Announcement
24 Jun '24
R&D Event Announcement
5 Jun '24
COVID-19 Trial Insight
21 May '24
Quarterly Report Filed
8 May '24
Annual Meeting Results
25 Apr '24
Annual Meeting Notice
4 Apr '24
Quarterly Update
21 Mar '24
InflaRx Filing
21 Mar '24
New Commitment Program
25 Jan '24
Positive Study Results
4 Jan '24
External Links:
SEC
InflaRx N.V. filed a report on May 7, 2025, providing their unaudited financial results for Q1 2025 and management's analysis.
AI Assistant
Close
INFLARX NV
2025
6 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.